Preclinical in-vitro and in-vivo studies were performed to validate the synergistic efficacy of the most effective HSP90 inhibitor and PI3K inhibitor combination in ACC cell lines, human ACC xenografts and patient-derived organoids (PDOs). This evidence concerns the gene PIK3CG and adrenal cortex carcinoma.